Skip to content

Trial · Observational

RecruitingPhase not statedRegistry data

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

NCTNCT05419726 (opens ClinicalTrials.gov in a new tab)Other id22-000718
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Recruiting
Phase
Phase not stated
Enrollment
20 participants (estimated)
Sponsor
University of California, Los Angeles · Other
Design
Not stated
Countries
1 country

United States

Start
1 Feb 2023
Primary completion
1 Jan 2026 (estimated)
Completion
1 Feb 2026 (estimated)
First posted
15 Jun 2022
Last update posted
11 May 2025
Conditions
Obesity

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20232024202520262027
  1. Ph –

    Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

    NCT05419726

    1 Feb 2023 to est. 1 Feb 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.

Interventions

  • Semaglutide Injectable Product (not provided by the study)Drug

Arms0

The registry lists no arms for this trial.

Primary outcomes3

Outcomes the sponsor listed as primary.

  1. change in supraclavicular temperature with cold exposure

    Time frame · 20weeks

    Registry description

    delta temperature

  2. change in caloric intake

    Time frame · 20weeks

    Registry description

    caloric intake

  3. basal metabolic rate

    Time frame · 20 weeks

    Registry description

    basal metabolic rate (ml O2/min or joule per hour per kg body mass)

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies6

Studies that cite this trial.

Studies with results

3 studies on this page

Indexing hint: Randomized controlled trial · 2020

3 results

Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.

van Eyk et al. 2020Nutrition, metabolism, and cardiovascular diseases : NMCDcited by 52

PMID 32127340DOI 10.1016/j.numecd.2019.12.005PUB-32127340

Full text at the publisher3 results
Publisher pageSee results (3)

Indexing hint: Randomized controlled trial · 2012

11 results

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

Horowitz et al. 2012Diabetes research and clinical practicecited by 140

PMID 22446097DOI 10.1016/j.diabres.2012.02.016PUB-22446097

Full text at the publisher11 results
Publisher pageSee results (11)

Indexing hint: Randomized controlled trial · 2004

6 results

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder et al. 2004Diabetes carecited by 176

PMID 15277417DOI 10.2337/diacare.27.8.1915PUB-15277417

Rights unknown6 results
Source linkSee results (6)

More studies

3 studies on this page

Indexing hint: Review · 2021

The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?

Stafeev et al. 2021Current molecular medicinecited by 3

PMID 33261539DOI 10.2174/1566524020666201201095029PUB-33261539

Full text at the publisher
Publisher page

Indexing hint: Animal study · 2021

Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue.

Oliveira et al. 2021Frontiers in endocrinologycited by 28

PMID 35069450PMC8771968DOI 10.3389/fendo.2021.803363PUB-35069450

CC BY
Download PDF

PubMed tag: none · 2014

GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.

Beiroa et al. 2014Diabetescited by 500

PMID 24917578DOI 10.2337/db14-0302PUB-24917578

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study) * \>18 years of age and willing to participate * Male or post-menopausal females Exclusion Criteria: * History of prior neck surgery and /or neck irradiation * Use of beta blocker agents * Use of any other glucose lowering medication * History of neuropathic disorders (e.g. diabetic neuropathy) * Diabetic patients * Individuals without normal thyroid function * Individuals with cancer * Any significant chronic disease or renal, hepatic or endocrine disease * Current smokers * Inability of patient to provide consent either for medical reasons or psychiatric reasons

PepBank is a research reference. Talk to a doctor before you use any peptide.